Fact: About half of women younger than 50 and one third of women older than 50 have dense breasts. Mammography is estimated to be only 48% effective in detecting breast cancers in dense breasts, compared to 98% effective in fatty breasts.

To better serve these patients, medical device manufacturer iCAD is expanding its partnership with Volpara. Now the VolparaAnalytics and VolparaDose solutions will be part of iCAD’s PowerLook Advanced Mammography platform along with VolparaDensity volumetric breast density assessment software.

“Today’s healthcare environment is increasingly data-driven and our customers require up-to-the-minute access to analytics that impact patient care,” said Ken Ferry, CEO of iCAD. “By incorporating additional breast imaging analytic and reporting solutions from Volpara, our PowerLook AMP customers will be able to go beyond automated mammography unit settings and mine patient-specific, real-time information for actionable insights regarding care delivery within their practices and across patient populations.”

VolparaDose personalizes the cancer treatment based upon the density of the patient’s breasts. VolparaAnalytics provides data from digital mammography units to reliably compare patient populations, mammography units, and operator performance. VolparaDensity assess density from both digital mammography and tomosynthesis images to help doctors evaluate who might benefit from additional screening. For more information, visit iCad.